Graphite Bio is a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases. Co.'s primary product candidate GPH101 is an approach with the potential to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression. Co.'s pipeline also includes GPH102 for beta-thalassemia and GPH201 for X-linked severe combined immunodeficiency syndrome; GPH301 for Gaucher disease and an early-stage research program for alpha-1 antitrypsin deficiency; and various undisclosed programs in both hematopoietic stem cells and other cell types. The GRPH stock yearly return is shown above.
The yearly return on the GRPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GRPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|